Graphite Bio PT From RBC Cut to $4 From $11 as Sickle Cell Disease Trial Pauses Amid Serious Adverse Event; Sector Perform, Speculative Risk Kept

MT Newswires · 01/06/2023 08:40

Please log in to view news